Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report

doi:10.12998/wjcc.v11.i35.8385

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1890)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

105

WORD

HTML

972

Figures (1-4)

204

Sum=1297

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

137

Download

382

Sum=519

Dec 16, 2023 (publication date) through Jan 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Dec 16, 2023; 11(35): 8385-8391
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8385

Full Size Figure Download Figure

Figure 3 Computed tomography. A: Multiple metastatic lesions in the abdominal cavity; B: Peritoneum; C: Abdominal wall.

Citation: Wu RT, Zhang JC, Fang CN, Qi XY, Qiao JF, Li P, Su L. Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report. World J Clin Cases 2023; 11(35): 8385-8391
URL: https://www.wjgnet.com/2307-8960/full/v11/i35/8385.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i35.8385